Could fewer radiation sessions mean fewer complications for sarcoma patients?
NCT ID NCT03819985
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a shorter, higher-dose radiation schedule given before surgery for soft tissue sarcoma of the arms, legs, or trunk. The goal is to see if this approach reduces wound complications after surgery while still controlling the cancer. About 122 patients are taking part, and researchers are comparing results to historical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hypofractionated radiation therapy
- What this could lead to
- If successful, this could offer a more convenient and safer pre-surgery radiation option for soft tissue sarcoma patients, with fewer wound complications.
- What could go wrong
- This is a mid-stage trial with only 122 participants, so results may not apply to all patients. The shorter radiation course might still cause wound problems or not control the cancer as well as standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could 5 days of radiation replace 25 for sarcoma patients?
- Experimental combo aims to boost immune attack on sarcoma before surgery
- New drug combo aims to stall rare Cancer's spread
- Can fewer, stronger radiation doses before sarcoma surgery reduce wound problems?
- New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
- Less scans, less stress? study tests smarter sarcoma surveillance